Starting with Exelixis’ condition on in-house dispensing data, manufacturers are introducing a new approach to 340B claims focused on transparency.
|Articles|October 2, 2020
Take Drug Topics' Annual Pharmacy Salary Survey
Every year, Drug Topics® asks pharmacists about their job experiences. Take our 2020 Annual Pharmacy Salary Survey here.
Advertisement
Every year, Drug Topics® asks pharmacists about their job experiences. We want to know about pharmacists' professional satisfaction—everything from salaries, raises, and bonuses to workload and stress levels.
Read more about
- Sixty-one percent of pharmacists said their stress levels increased at work in 2019 compared to 2018.
- The average salary reported in the 2010 survey was lower ($100,000-$130,000) compared to 2019, with nearly 50% of pharmacists in 2019 who said they make over the $130,000 mark.
- More than 18% of pharmacists said they were "extremely satisified" with their job compared to 9% of those who said they were "extremely dissatisfied".
- Common stress contributors cited in the 2019 survey included vaccination quotas, DIR fees, and new USP regulations.
Advertisement
Related to this article
The trial found that up to 25 days of nirmatrelvir-ritonavir did not improve cognitive, autonomic, or exercise-related symptoms compared with placebo.
Digital innovation and proactive patient care are converging to transform clinical practice while preserving essential safeguards.
James Barnes, CPhT, explains why respecting a patient's time isn't about speed and how he landed in the pharmacy by chance.
ACIP changes, new court rulings, and coverage gaps threaten vaccines, pharmacists’ reimbursement, and children's access through Vaccine For Children.
As pouched products increase in popularity, researchers assess their pharmacology, harm-reduction potential, and initiation risk.
The approval is the first new treatment advance in more than 30 years for chronic kidney disease for adults with type 1 diabetes.
Adults with serious mental illness receive GLP-1 prescriptions at rates similar to or higher than their peers, though schizophrenia continued to lag.
Advertisement
Advertisement
Trending on Drug Topics
1
Nicotine Pouches Create Opportunity for Pharmacist Counseling
2
Johnson & Johnson Next Major Drugmaker to Require 340B Claims Data
3
Worth a Shot: How ACIP Changes Might Impact Vaccine Access, Coverage
4
FDA Approves Finerenone for Chronic Kidney Disease With Type 1 Diabetes
5